SCHEMBL10757337

SCHEMBL10757337

Cc1cc2cnc(N)nc2o1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.36
FGFR1 P11362 1/20 0.36
LCK P06239 1/20 0.35
KDR P35968 1/20 0.35
JAK3 P52333 1/20 0.35
MAPK14 Q16539 1/20 0.35
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
NUDT1 P36639 5/20 0.33
CSNK1D P48730 1/20 0.33
CSNK1E P49674 1/20 0.33
CLK1 P49759 1/20 0.33
PDPK1 O15530 1/20 0.32
ADORA1 P30542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5925825 0.79 ALDH1A1 (0.39) KDRALDH1A1PKM
SCHEMBL18769964 0.76 ALDH1A1 (0.38) KDRALDH1A1PKM
SCHEMBL23473972 0.71 DYRK1A (0.50) DYRK1AFGFR1NOS3NOS1NOS2
SCHEMBL8984136 0.69 HTR2C (0.35) DYRK1AKDRALDH1A1PKM
SCHEMBL11009871 0.69 RAB9A (0.46) ADORA1
SCHEMBL10761005 0.68 ALDH1A1 (0.58) KDRALDH1A1PKMNUDT1
SCHEMBL7926339 0.67 CCR1 (0.45) DYRK1AKDRNOS3NOS1NOS2
SCHEMBL20893550 0.67 NOS3 (0.38) DYRK1AFGFR1NOS3NOS1NOS2
SCHEMBL22836114 0.67 NOS3 (0.38) DYRK1AFGFR1NOS3NOS1NOS2
SCHEMBL10957730 0.65 ALDH1A1 (0.42) KDRALDH1A1PKMADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452465-B1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES GENOSCIENCE PHARMA (FR) 2020-11-04 EP disclosed
US-10577362-B2 Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases GENOSCIENCE PHARMA (FR) 2020-03-03 US disclosed
US-20190144437-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES GENOSCIENCE PHARMA (FR) 2019-05-16 US disclosed
EP-3452465-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES Genoscience Pharma SAS (FR) 2019-03-13 EP disclosed
WO-2017191599-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES GENOSCIENCE PHARMA (FR) 2017-11-09 WO disclosed
US-4680053-A Herbicidal alkenyl sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-07-14 US disclosed
US-4461640-A REACTING SULFUR, POLYHALOGENATED AROMATIC, AN ALDEHYDE AND A CAUSTIC ALKALI E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-07-24 US disclosed
EP-0085236-A1 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144437-A1 SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES NQO2, RECQL, CCNO DYRK1A 1635/4885FGFR1 634/4885LCK 955/4885
US-10577362-B2 Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases NQO2, RECQL, CCNO DYRK1A 1635/4885FGFR1 634/4885LCK 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.